Hot Features
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral ... Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 2.99 | 27.7365491651 | 10.78 | 14.2771 | 10.3 | 123144 | 11.60176116 | CS |
| 4 | 3.32 | 31.7703349282 | 10.45 | 14.2771 | 9.115 | 141838 | 10.72189085 | CS |
| 12 | 2.07 | 17.6923076923 | 11.7 | 14.2771 | 9.115 | 125785 | 11.09151952 | CS |
| 26 | 5.74 | 71.4819427148 | 8.03 | 14.93 | 7.37 | 125532 | 10.18342558 | CS |
| 52 | 5.74 | 71.4819427148 | 8.03 | 14.93 | 7.37 | 105855 | 10.05213911 | CS |
| 156 | -7.69 | -35.834109972 | 21.46 | 22.65 | 2.96 | 63914 | 8.58749992 | CS |
| 260 | -0.23 | -1.64285714286 | 14 | 24.39 | 2.96 | 64746 | 8.72276176 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.